A Comparative Clinical Study of Jalauka-Avcharan & Vidangadi Lepa in the Management of Dadru (Dermatophytosis)
Trial Snapshot
- Phase
- Phase 3 4
- Status
- Not yet recruiting
- Sponsor
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- Relief in redness & Itching
Study Overview
Brief Summary
This study is an Interventional Open and Randomized group trial study, named- A COMPARATIVE CLINICAL STUDY OF JALAUKA-AVCHARAN AND VIDANGADI LEPA IN THE MANAGEMENT OF DADRU (DERMATOPHYTOSIS).
A total number of 60 patients suffering from dadru will be randomly selected from OPD and IPD of Government PG Ayurveda College and Hospital, Varanasi and will be divided into three groups, each group having 20 patients.
Group A- 20 patients will be treated with RAKTAMOKSHAN with the help of Jalauka of duration 17 days in three sittings.
Group B- 20 patients will be treated with Vidangadi Lepa of duration 17 days.
Group c- 20 patients will be given combined treatment of raktamokshan by jalauka along with Vidangadi Lepa of duration 17 days.
Follow up- After completion of treatment course of 17 days, there will be three follow ups at the interval of seven days.
First Follow up- At 7th day
Second Follow up- At 14th day
Third Follow up- At 21st day
Study Design
- Study Type
- Interventional
- Allocation
- Coin toss, Lottery, toss of dice, shuffling cards etc
- Masking
- Open Label
Eligibility Criteria
- Ages
- 16.00 Year(s) to 70.00 Year(s) (—)
- Sex
- All
Inclusion Criteria
- •1 Patients are selected irrespective of sex occupation caste etc 2 Patients between age group 16 to 70 years are included in the study 3 Patients with classical sign and symptoms of Dadru will be taken 4 Patients having Hb value within normal range more than 10 mg per dl.
Exclusion Criteria
- •1 Patient of age group less than 16 and and more than 70 years 2 Patient who lies in the criteria of Raktamokshan Ayogya 3 Patients having Hb below 10mg per dl 4 Immuno-compromised patient Uncontrolled Diabetes Skin Cancer etc 5 Any haemorrhagic disorder or hereditary conditions Thallesemia Sickle cell anemia etc 6 Pregnant and Lactating mothers.
Outcomes
Primary Outcomes
Relief in redness & Itching
Time Frame: 10 days
Secondary Outcomes
- Reduction in lesion size(17 days)